PL378057A1 - Zastosowanie enancjomerów (1S, 2R) milnacypranu do wytwarzania leku - Google Patents

Zastosowanie enancjomerów (1S, 2R) milnacypranu do wytwarzania leku

Info

Publication number
PL378057A1
PL378057A1 PL378057A PL37805704A PL378057A1 PL 378057 A1 PL378057 A1 PL 378057A1 PL 378057 A PL378057 A PL 378057A PL 37805704 A PL37805704 A PL 37805704A PL 378057 A1 PL378057 A1 PL 378057A1
Authority
PL
Poland
Prior art keywords
active
serotonin
noradrenaline
capture
enantiomer
Prior art date
Application number
PL378057A
Other languages
English (en)
Other versions
PL219671B1 (pl
Inventor
Jean Deregnaucourt
Richard Grosse
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0301849A external-priority patent/FR2851163B1/fr
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of PL378057A1 publication Critical patent/PL378057A1/pl
Publication of PL219671B1 publication Critical patent/PL219671B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL378057A 2003-02-14 2004-02-16 Zastosowanie enancjomeru (1S, 2R) milnacypranu do wytwarzania leku PL219671B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301849A FR2851163B1 (fr) 2003-02-14 2003-02-14 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
US10/453,574 US7005452B2 (en) 2003-02-14 2003-06-03 Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug

Publications (2)

Publication Number Publication Date
PL378057A1 true PL378057A1 (pl) 2006-02-20
PL219671B1 PL219671B1 (pl) 2015-06-30

Family

ID=32929266

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378057A PL219671B1 (pl) 2003-02-14 2004-02-16 Zastosowanie enancjomeru (1S, 2R) milnacypranu do wytwarzania leku

Country Status (20)

Country Link
US (2) US7074833B2 (pl)
EP (2) EP1908461B9 (pl)
KR (1) KR101185322B1 (pl)
AT (1) ATE401872T1 (pl)
AU (1) AU2004216452B2 (pl)
BR (1) BRPI0407256A (pl)
CA (1) CA2514948C (pl)
DE (1) DE602004015257D1 (pl)
DK (1) DK1601349T3 (pl)
ES (1) ES2310715T3 (pl)
HK (1) HK1079117A1 (pl)
MA (1) MA27655A1 (pl)
MX (1) MXPA05008652A (pl)
NO (1) NO333987B1 (pl)
NZ (1) NZ541733A (pl)
PL (1) PL219671B1 (pl)
PT (1) PT1601349E (pl)
RU (1) RU2317817C2 (pl)
SI (1) SI1601349T1 (pl)
WO (1) WO2004075886A1 (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2008031928A1 (fr) * 2006-09-14 2008-03-20 Pierre Fabre Medicament Utilisation du milnacipran pour diminuer les proprietes recompensantes de l'alcool pendant ou apres un traitement de sevrage alcoolique
CN101195583B (zh) 2006-12-04 2012-07-04 四川抗菌素工业研究所有限公司 一种光学纯米那普仑及其盐的制备方法
WO2009023820A1 (en) * 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
EP2110129A1 (en) * 2008-04-18 2009-10-21 Pierre Fabre Medicament Use of enantiomer (1S, 2R) milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
CA2733122A1 (en) * 2008-09-04 2010-03-11 United Parcel Service Of America, Inc. Determining vehicle visit costs to a geographic area
US8865937B2 (en) * 2009-11-06 2014-10-21 Mahendra G. Dedhiya Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
JP2013517290A (ja) * 2010-01-14 2013-05-16 ピエール ファーブル メディカモン レボミルナシプランの安定した剤形
WO2011158249A1 (en) * 2010-06-16 2011-12-22 Glenmark Generics Limited Process for preparation of milnacipran intermediate and its use in preparation of pure milnacipran
WO2012059933A1 (en) 2010-11-03 2012-05-10 Arch Pharmalabs Limited A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts.
WO2012145234A2 (en) * 2011-04-21 2012-10-26 Emory University Cyclopropyl derivatives and methods of use
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
EA029151B1 (ru) * 2011-09-06 2018-02-28 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CN104603096A (zh) 2012-05-07 2015-05-06 塞利克斯比奥私人有限公司 用于治疗神经肌肉障碍和神经退行性疾病的组合物和方法
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013168002A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US10379551B2 (en) 2013-07-10 2019-08-13 Crowdcomfort, Inc. Systems and methods for providing augmented reality-like interface for the management and maintenance of building systems
US10070280B2 (en) 2016-02-12 2018-09-04 Crowdcomfort, Inc. Systems and methods for leveraging text messages in a mobile-based crowdsourcing platform
US11394462B2 (en) 2013-07-10 2022-07-19 Crowdcomfort, Inc. Systems and methods for collecting, managing, and leveraging crowdsourced data
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
AU2014407862B2 (en) 2014-09-29 2020-03-26 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain
CN111620807A (zh) * 2019-02-27 2020-09-04 北京万全德众医药生物技术有限公司 一种盐酸左旋米那普仑杂质的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
FR2746314B1 (fr) 1996-03-25 1998-06-12 Pf Medicament Produit contenant du milnacipran et de l'idazoxan comme preparation pharmaceutique combinee
FR2752732B1 (fr) * 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
FR2759290B1 (fr) 1997-02-13 2004-06-18 Pf Medicament Minalcipran pour le traitement de l'incontinence urinaire
FR2759906B1 (fr) * 1997-02-21 2004-06-04 Pf Medicament Utilisation de milnacipran et de ses derives pour la preparation d'un medicament destine au traitement de certaines maladies psychiatriques
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
US6635675B2 (en) * 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
EP1482921A1 (en) 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
EP1558231A4 (en) 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy

Also Published As

Publication number Publication date
MXPA05008652A (es) 2005-10-18
EP1908461B1 (fr) 2011-03-16
ES2310715T3 (es) 2009-01-16
EP1601349A1 (fr) 2005-12-07
HK1079117A1 (en) 2006-03-31
WO2004075886A1 (fr) 2004-09-10
PL219671B1 (pl) 2015-06-30
SI1601349T1 (sl) 2008-10-31
ATE401872T1 (de) 2008-08-15
EP1908461B9 (fr) 2011-08-31
DE602004015257D1 (de) 2008-09-04
NO20054228L (no) 2005-09-12
CA2514948A1 (fr) 2004-09-10
US20040259953A1 (en) 2004-12-23
PT1601349E (pt) 2008-10-27
AU2004216452A1 (en) 2004-09-10
EP1908461A1 (fr) 2008-04-09
CA2514948C (fr) 2013-04-02
BRPI0407256A (pt) 2006-01-31
EP1601349B1 (fr) 2008-07-23
AU2004216452B2 (en) 2008-10-16
KR20050096190A (ko) 2005-10-05
NO333987B1 (no) 2013-11-04
RU2317817C2 (ru) 2008-02-27
NZ541733A (en) 2009-03-31
MA27655A1 (fr) 2005-12-01
US20060014837A1 (en) 2006-01-19
RU2005128548A (ru) 2006-01-20
KR101185322B1 (ko) 2012-09-21
US7074833B2 (en) 2006-07-11
DK1601349T3 (da) 2008-10-27

Similar Documents

Publication Publication Date Title
HK1079117A1 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
IL201038A0 (en) Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament
AP2001002252A0 (en) Monoamine reuptake inhibitors for treatment of CNS disorders.
AP2002002481A0 (en) Biaryl ether derivatives useful as monoamine reuptake inhibitors.
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
EA200500776A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА И ИНГИБИТОР ОБРАТНОГО ЗАХВАТА СЕРОТОНИНА И/ИЛИ НОРЭПИНЕФРИНА, И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ ФУНКЦИИ МОЧЕВОГО ПУЗЫРЯ
ZA200600343B (en) Substituted 2-aminotetralin for the treatment of depression
RU2008127882A (ru) Лечение пищевода барретта
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
RU2007126638A (ru) Профилактическое или терапевтическое средство для лечения расстройства сна
DK1322305T3 (da) Anvendelse af R-arylpropionsyrer til fremstilling af lægemidler til behandling af lidelser af rheumatisk natur
TW200507853A (en) Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
WO2008085872A8 (en) Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
SE0203778D0 (sv) A new oral immediated release dosage form
ATE506348T1 (de) Neue benzoylpiperidinverbindungen
SE9803157D0 (sv) A new composition
SE9803155D0 (sv) A new composition
HUP0301863A2 (hu) Szorongásos megbetegedések gyógyítása szelektív norepinefrin visszavétel gátló hatású vegyületekkel

Legal Events

Date Code Title Description
DISD Decisions on discontinuance of the proceedings of a derived patent or utility model

Ref document number: 402987